A study by Cecchini et al published in JAMA Oncology sought to determine if perioperative 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) improves survival in patients with resectable pancreatic ductal adenocarcinoma.
Question 1 of 5
What is NOT part of the rationale for incorporating neoadjuvant modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFIRINOX) into the management of resectable pancreatic ductal adenocarcinoma?
